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Available online 23 February 2016Background & aims: Blood aspartate aminotransferase (AST) and alanine transaminase (ALT) levels are the most
frequently reliable biomarkers of liver injury. AlthoughAST and ALT play central roles in glutamate production as
transaminases, peripheral blood levels of AST and ALT have been regarded only as liver injury biomarkers. Glu-
tamate is a principal excitatory neurotransmitter, which affects memory functions in the brain. In this study,
we investigated the impact of blood transaminase levels on blood glutamate concentration and memory.
Methods: Psychiatrically, medically, and neurologically healthy subjects (n = 514, female/male: 268/246) were
enrolled in this study through local advertisements. Plasma amino acids (glutamate, glutamine, glycine, D-serine,
and L-serine) were measured using a high performance liquid chromatography system. The ﬁve indices, verbal
memory, visual memory, general memory, attention/concentration, and delayed recall of theWechsler Memory
Scale-Revised were used to measure memory functions.
Results: Both plasma AST and ALT had a signiﬁcant positive correlation with plasma glutamate levels. Plasma AST
andALT levelswere signiﬁcantly negatively correlatedwith four ofﬁvememory functions, and plasma glutamate
was signiﬁcantly negatively correlated with three of ﬁvememory functions. Multivariate analyses demonstrated
that plasma AST, ALT, and glutamate levels were signiﬁcantly correlated with memory functions even after ad-
justment for gender and education.
Conclusions:As far aswe know, this is the ﬁrst reportwhich could demonstrate the impact of blood transaminase
levels on blood glutamate concentration and memory functions in human. These ﬁndings are important for the
interpretation of obesity-induced metabolic syndrome with elevated transaminases and cognitive dysfunction.
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. This is an open access article undersimply as liver injury biomarkers [1,2]. In various etiologies from viral
hepatitis to nonalcoholic fatty liver disease (NAFLD), blood AST and
ALT levels are elevated and are frequently reliable biomarkers of hepa-
totoxic effects. However, AST and ALT also play central roles in amino
acid metabolism as transaminases [1,2]. Speciﬁcally, AST and ALT cata-
lyze transamination from aspartate or alanine to glutamate and are im-
portant positive regulators of tissue glutamate levels [1,3]. In addition, a
previous report demonstrated that transaminases in human blood have
efﬁcient enzymatic transamination activity [4]. However, there are no
reports that have demonstrated the correlation between blood trans-
aminases and glutamate levels in human subjects.
Glutamate plays pivotal roles in many physiological brain functions
includingmemory [5,6]. Glutamate is a principal excitatory neurotrans-
mitter of the central nervous system [7]. Memory dysfunction can affect
our cognitive function, and peripheral blood glutamate levels have been
reported to be altered in many cognitive function disorders, such asthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Characteristics of the study subjects.
Number 514
Age (years) 31.8 ± 12.3
Gender (F/M) 268/246
Education (years) 15.0 ± 1.8
AST (U/L) 19.1 ± 6.6
ALT (U/L) 17.3 ± 12.9
Gln (μM) 528.4 ± 72.7
Gly (μM) 223.0 ± 54.8
Glu (μM) 32.9 ± 16.4
D-Serine (μM) 0.95 ± 0.32
L-Serine (μM) 119.7 ± 27.4
Verbal memory 112.9 ± 13.7
Visual memory 105.0 ± 9.6
General memory 112.4 ± 13.0
Attention/concentration 110.1 ± 12.7
Delayed recall 110.0 ± 12.2
Data are presented as the mean ± standard deviation (S.D.).
Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotrans-
ferase; Gln, glutamine; Gly, glycine; Glu, glutamate.
102 Y. Kamada et al. / BBA Clinical 5 (2016) 101–107Asperger's syndrome [8] and schizophrenia [9]. The glutamate con-
centration in the blood is thought to have effects on brain function
despite the existence of the blood brain barrier (BBB). Indeed, pe-
ripheral blood glutamate levels positively correlate with the concen-
tration of glutamate in cerebrospinal ﬂuid (CSF) [10,11]. In rodent
models, systemic administration of monosodium glutamate (MSG)
induces BBB breakdown through its hypertonic effect [12]. There
have been many reports that have demonstrated that glutamate
and glutamatergic receptor have signiﬁcant effects on memory func-
tions [13,14]. One of the mechanisms by which glutamate affects
memory function is through glutamatergic induction of long term
potentiation (LTP) of synaptic strength thorough activation of
calcium/calmodulin-dependent protein kinase II (CaMKII) [15].
In consideration of these ﬁndings, we hypothesized that blood
transaminase levels could change the blood glutamate concentration
and would have signiﬁcant effects on cognitive functions in humans.
To conﬁrm our hypothesis, we investigated the relationship between
blood transaminase (AST and ALT) levels, brain function-related
amino acid levels [glutamine, glutamate, glycine, D-serine, and L-serine],
and memory functions (verbal memory, visual memory, general mem-
ory, attention/concentration, and delayed recall) in 514 healthy sub-
jects without any psychological diseases or current medication.
2. Materials and methods
2.1. Ethical committee approval
The protocol and informed consent document were approved by
the institutional review boards at Osaka University Graduate School
of Medicine and Chiba University (No. 592). Written informed con-
sent was obtained from all subjects and the study was conducted in
accordance with the Helsinki Declaration.
2.2. Memory function assessment and laboratory measurements
A full version of theWMS-R [16,17], a measure that is generally used
tomeasurememory,was administered to the subjects, as previously de-
scribed [18]. The ﬁve indices, verbal memory, visual memory, general
memory, attention/concentration, and delayed recall of the WMS-R
were used in the analysis. The scores of indices were corrected by age.
Memory functions were positively correlated with the scores of indices.
The mean value of these scores was set to 100, and one standard devia-
tion (S.D.) was deﬁned as 15. Blood biochemical variables [aspartate
aminotransferase (AST) and alanine aminotransferase (ALT)] were
measured with a conventional automated analyzer (Mitsubishi
MEDIENCE, Kobe, Japan).
2.3. Determination of plasma amino acid levels
Measurement of plasma D-serine and L-serinewere carried out using
a column-switching high performance liquid chromatography (HPLC)
system (Shimadzu Corporation, Kyoto, Japan) [19,20]. Measurement of
plasma glutamine, glutamate, and glycine was carried out using an
HPLC system with ﬂuorescence detection, as previously described [21].
2.4. Study subjects
A total of 514 healthy volunteers were enrolled in this study, as pre-
viously described [22,23]. The study subjects were recruited through
local advertisements. Psychiatrically, medically, and neurologically
healthy subjects were evaluated using the structured clinical interview
for DSM-IV (SCID), non-patient version. Subjects were excluded if they
had neurological or medical conditions that could potentially affect the
central nervous system, such as atypical headache, head trauma with
loss of consciousness, chronic lung disease, kidney disease, chronic thy-
roid disease, active stage cancer, cerebrovascular disease, epilepsy, orseizures. The criteria for exclusion from this study also included a histo-
ry of known hepatic diseases and virus hepatitis marker positive sub-
jects (HCV-antibody and HBs antigen). The detailed information
regarding the subjects is shown in Table 1. Brieﬂy, the gender ratio
was 268/246 (female/male), mean age was 31.8 ± 12.3 years old, and
mean education length was 15.0 ± 1.8 years.
2.5. Statistical analysis
Statistical analysis was conducted using JMP Pro 11.0 (SAS Institute
Inc., Cary, NC) and SPSS 20.0 (SPSS Japan Inc., Tokyo, Japan) software.
Variables were expressed as mean ± S.D. As AST, ALT, glutamate,
glycine, D-serine, and L-serine did not show a Gaussian distribution,
these parameters were common log-transformed before analysis. The
Wilcoxon test and Spearman R correlations were used for the statistical
analyses in this study. Multivariate logistic regression analyses were
conducted to identify parameters that signiﬁcantly contribute to each
memory function. Differences were considered statistically signiﬁcant
at P b 0.05.
3. Results
3.1. Plasma transaminase (AST and ALT) levels signiﬁcantly correlate with
the plasma glutamate level
AST and ALT are transaminases which catalyze transamination from
aspartate or alanine to glutamate. However, as far aswe know, there are
no reports that have investigated the relationship between blood trans-
aminase and glutamate levels. First, we investigated the correlation be-
tween plasma transaminase levels and glutamate levels in our subjects.
As expected, we found a signiﬁcant and positive correlation between
transaminases (AST and ALT) and glutamate (AST: R = 0.19, P =
1.1 × 10−5; ALT: R= 0.30, P=5.0 × 10−12) (Fig. 1, Table 2). Both plas-
maAST and ALT levels had signiﬁcant negative correlationswith plasma
glycine and L-serine [AST: R = −0.12, P = 7.2 × 10−3 (glycine),
R = −0.22, P = 7.5 × 10−7 (L-serine); ALT: R = −0.16, P =
3.5 × 10−4 (glycine), R = −0.24, P = 6.5 × 10−8 (L-serine)]. There
were no signiﬁcant correlations between plasma transaminases and
other amino acids [(AST: R = −0.043, P = 0.34 (glutamine), R =
0.074, P = 0.095 (D-serine); ALT: R =−5.3 × 10−3, P = 0.91 (gluta-
mine), R = 0.013, P= 0.77 (D-serine)]. A previous report has demon-
strated that blood transaminases have enzymatic transamination
activity [4]. Our results indicate that the blood transaminase concentra-
tion deﬁnes the concentration of peripheral blood glutamate in human
subjects.
Fig. 1.Relationships between plasma transaminase level and plasma glutamate level. Relationships between the plasma glutamate level and (A) plasmaAST level and (B) plasmaALT level.
LogGlu, common log-transformed glutamate; LogAST, common log-transformed AST; LogALT, common log-transformed ALT.
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and memory functions
Next, we investigated the relationships between plasma transami-
nase levels andmemory functions (Fig. 2) and between amino acid levels
and memory functions (Table 3). Both plasma AST and ALT levels were
signiﬁcantly and negatively correlated with four of ﬁve memory func-
tions [verbal memory: R =−0.11, P = 0.014 (AST), R =−0.13, P =
4.0 × 10−3 (ALT); visual memory: R = −0.11, P = 0.012 (AST),
R = −0.11, P = 0.014 (ALT); general memory: R = −0.13, P =
0.0044 (AST), R = −0.14, P = 0.0013 (ALT); and delayed recall:
R =−0.13, P= 0.0033 (AST), R =−0.15, P= 4.0 × 10−4 (ALT)] (Fig.
2A, B, C, E), but were not correlated with attention/concentration
(R=−0.022, P=0.61) (Fig. 2D). Plasmaglutamate levels demonstrated
a similar correlation as transaminases with memory functions (Table 3).
Other amino acids (glutamine, glycine, D-serine, and L-serine) did not
correlate with verbal, visual, or general memory or delayed recall.
As shown above, plasma AST, ALT, and glutamate levels were signif-
icantly correlated with verbal, visual, and general memory and delayed
recall. To exclude the effects of gender differences and level of educa-
tion, we conductedmultivariate analyses for eachmemory function ad-
justed for gender and years of education (Table 4A, B, C). Plasma AST
level was a signiﬁcant determinant for verbal, visual, and general mem-
ory anddelayed recall. PlasmaALT levelwas a signiﬁcant determinant of
verbal and general memory and delayed recall. Plasma glutamate level
was a signiﬁcant determinant of verbal, general memory, and delayed
recall. These results indicate that plasma AST, ALT, and glutamate levels
are signiﬁcantly correlated with memory functions even after adjust-
ment for gender and education length.4. Discussion
In the present study, we demonstrated the correlations among plas-
ma transaminase levels, amino acid levels, andmemory functions. As farTable 2
Correlation between plasma transaminases and amino acids.
AST ALT
R P value R P value
Glu 0.19 1.1 × 10−5 0.30 5.0 × 10−12
Gln −0.043 0.34 −0.0053 0.91
Gly −0.12 7.2 × 10−3 −0.16 3.5 × 10−4
D-Serine 0.074 0.095 0.013 0.77
L-Serine −0.22 7.5 × 10−7 −0.24 6.5 × 10−8aswe know, our study is theﬁrst report to demonstrate that plasmaAST
andALT have signiﬁcant positive correlationswith peripheral blood glu-
tamate concentrations and signiﬁcant negative correlations with mem-
ory functions in healthy subjects. In addition, we found that plasma
glutamate levels also have signiﬁcant and negative relationships with
memory functions. Our ﬁndings indicate that plasma transaminase
levels have signiﬁcant impact on memory functions through changes
in plasma glutamate concentration.
AST and ALT have been known to have critical roles in glutamate
production [1,3,4]. Glutamate is known to be the major excitatory neu-
rotransmitter of the central nervous system [7] and plays many impor-
tant roles in brain functions. Plasma glutamate levels positively
correlatewith the CSF glutamate concentration [10,11]. Inmale patients
with schizophrenia, plasma levels of glutamate are elevated compared
with those in control subjects [9]. A meta-analysis has also demonstrat-
ed that peripheral glutamate levels in schizophrenia patients are signif-
icantly higher than in controls [24]. In addition, signiﬁcant correlations
have been reported in various cognitive disorder diseases between
brain glutamate levels and disease symptoms [13]. Therefore, although
we did not measure CSF glutamate levels, increased plasma glutamate
levelswould have signiﬁcant effects on brain functions. On the contrary,
there have been some reports that have demonstrated no signiﬁcant re-
lationships between blood glutamate levels and cognitive functions in
schizophrenia patients [25–27]. Drugs used in these patients would
not have any effects on serum glutamate concentration and cognitive
functions, and the relationships would be diminished in these patients.
In our study, we have demonstrated signiﬁcantly positive relationships
between peripheral blood glutamate and these transaminases. We also
found that both plasma transaminases and glutamate levels in healthy
subjectswere negatively correlatedwithmemory functions. Theseﬁnd-
ings indicate that elevation of plasma transaminase levels induces
memory dysfunction through plasma glutamate level elevation in
healthy subjects under no medication.
Recent studies have demonstrated that brain dysfunction induces
food addiction and obesity [28,29]. Binge eating disorder is character-
ized by a compulsive engagement in excessive food consumption
which results in obesity [30]. In particular, glutamate and glutamate re-
ceptors have been found to play a role in the regulation of food intake
and modiﬁcation of binge eating (known as the “glutamate hypothe-
sis”) [31–33]. MSG administration in rodent models is often used to in-
duce overeating and obesity [34,35]. In humans, glutamateN-methyl-D-
aspartate (NMDA) receptor agonist suppresses food intake, and the
NMDA receptor antagonist, acamprosate, has been found to decrease
food dependency and weight gain [32,36–38]. These ﬁndings indicate
that glutamatergic system regulation may be useful for the treatment
of eating disorders and obesity. In the DSM-4 (Diagnostic and Statistical
104 Y. Kamada et al. / BBA Clinical 5 (2016) 101–107Manual of Mental Disorders, Forth Edition), substance addiction is
deﬁned as a cluster of cognitive, behavioral, and psychological symp-
toms associated with the continuous use of a substance despite sig-
niﬁcant problems caused by the substance [39]. While obesity is
characterized by overeating and the inability to stop overeating de-
spite the desire to do so, these symptoms are remarkably parallel
to those described in the DSM-4 for substance addiction. Therefore,
some forms of obesity should be included as amental disorder driven
by a food addiction [40]. Obesity is not only closely associated with
fatty liver disease, but also induces cognitive dysfunction [41–43].
Considered together, transaminase elevation in obesity-related
fatty liver patients may trigger cognitive dysfunction and food addic-
tion and might induce further weight gain.Fig. 2. Relationships between plasma transaminase level and memory functions. (A) Relation
plasma transaminase level and visual memory. (C) Relationship between plasma transamina
attention/concentration. (E) Relationship between plasma transaminase level and delayed recOther amino acids, such as glutamine, glycine, D-serine, and L-serine,
also have signiﬁcant effects on brain functions [21,44,45]. Among these
amino acids, D-serine and glycine are known as co-agonists of the
NMDA receptor, and facilitate excitatory glutamatergic neurotransmis-
sion at synapses within the nervous systems [46–48]. Because phency-
clidine, a non-competitive antagonist of the NMDA receptor, induces
schizophrenia-like symptoms in healthy subjects, recent research on
schizophrenia has focused on hypofunction of the NMDA receptor.
However, no signiﬁcant correlations have been cited between these
amino acids (glycine and D-serine) and memory functions in our study
subjects.
Obesity is a central and causal component of metabolic syndrome
(Mets) and is almost always induced by overeating resulting fromship between plasma transaminase level and verbal memory. (B) Relationship between
se level and general memory. (D) Relationship between plasma transaminase level and
all.
Fig. 2 (continued).
105Y. Kamada et al. / BBA Clinical 5 (2016) 101–107food addiction [29,49]. Mets, a cluster of obesity-related diseases in-
cluding NAFLD, is a critical growing medical problem in industrial-
ized countries of the world. NAFLD is among the most common
causes of chronic liver disease in obese people [41]. NAFLD patients
have food dependency [50], and weight reduction is useful for the
prevention of NAFLD progression [51,52]. However, clinical
hepatologists often encounter NAFLD patients who do not stop over-
eating in spite of frequent nutritional guidance [50]. In the rodent
fatty liver model, it has been reported that memory performance is
impaired and exenatide (glucagon-like peptide-1 analog) treatment
improves memory performance [53]. In addition, 85% of NAFLD pa-
tients havemild or moderate cognitive dysfunction [54]. We suppose
a number of the subjects in the present study with elevated transam-
inase levels would have NAFLD. In NAFLD patients, cognitive dys-
function induced by transaminase elevation has some effect onTable 3
Correlation between plasma amino acids and memory functions.
Glu Gln
R P value R P value
Verbal memory −0.12 8.6 × 10−3 −0.031 0.48
Visual memory −0.084 0.056 −0.058 0.19
General memory −0.13 3.4 × 10−3 −0.038 0.39
Attention/concentration 0.043 0.33 0.088 0.046
Delayed recall −0.12 7.8 × 10−3 −0.0096 0.83their food dependency. A cross-sectional and longitudinal study is
needed to elucidate the relationships among blood transaminase
levels, glutamate levels, and memory functions in NAFLD patients.
Our study has some limitations. First, our study is a cross-
sectional study. The effects of a plasma transaminase level change
on plasma glutamate levels and memory functions were not eluci-
dated. Longitudinal studies are needed to investigate this issue in
more detail. Second, our study lacks the inclusion of factors related
toMets, such as body weight, blood sugar, and lipid levels. Therefore,
the effects of factors other than transaminase and glutamate levels
on memory functions were not assessed in our study. However, our
study has a strong advantage in terms of the large number of healthy
subjects (n = 514) included. Our healthy subjects were under no
medication and did not have any past history of psychiatric diseases
with memory dysfunction. Therefore, we believe a meaningfulGly D-Serine L-Serine
R P value R P value R P value
−0.018 0.69 0.05 0.25 −0.006 0.90
−7.0 × 10−4 0.99 0.046 0.30 0.024 0.59
−0.011 0.80 0.059 0.18 −0.006 0.90
−0.031 0.49 0.048 0.28 −0.098 0.027
−9.0 × 10−3 0.84 0.092 0.037 −0.003 0.95
Table 4
Multiple logistic regression analyses of factors associated with each memory function.
Factors Estimated value S.E. t value P value
(A) Model 1 (gender, education, AST)
Verbal memory
Gender (male) −0.48 0.62 −0.77 0.44
Education (years) 0.83 0.34 2.45 0.014
AST (U/L) −0.23 0.092 −2.5 0.013
Visual memory
Gender (male) −0.53 0.44 −1.23 0.22
Education length (years) 0.063 0.24 0.27 0.79
AST (U/L) −0.15 0.065 −2.26 0.024
General memory
Gender (male) −0.51 0.59 −0.87 0.38
Education (years) 0.69 0.32 2.15 0.032
AST −0.25 0.087 −2.83 4.9 × 10−3
Delayed recall
Gender (male) −0.57 0.55 −1.04 0.30
Education (years) 0.89 0.30 2.99 2.9 × 10−3
AST (U/L) −0.23 0.082 −2.8 5.3 × 10−3
(B) Model 2 (gender, education, ALT)
Verbal memory
Gender (male) −0.23 0.64 −0.36 0.72
Education (years) 0.82 0.34 2.43 0.016
ALT (U/L) −0.14 0.048 −2.91 3.7 × 10−3
Visual memory
Gender (male) −0.50 0.45 −1.11 0.27
Education (years) 0.068 0.24 0.29 0.77
ALT (U/L) −0.053 0.034 −1.58 0.12
General memory
Gender (male) −0.28 0.60 −0.47 0.64
Education (years) 0.68 0.32 2.13 0.034
ALT (U/L) −0.14 0.046 −3.04 2.5 × 10−3
Delayed recall
Gender (male) −0.36 0.56 −0.63 0.53
Education (years) 0.88 0.30 2.97 3.2 × 10−3
ALT (U/L) −0.13 0.043 −3.03 2.6 × 10−3
(C) Model 3 (gender, education, glutamate)
Verbal memory
Gender (male) −0.035 0.66 −0.05 0.96
Education (years) 0.86 0.34 2.55 0.011
Glu (μM) −0.11 0.039 −2.79 5.5 × 10−3
Visual memory
Gender (male) −0.46 0.47 −1 0.32
Education (years) 0.084 0.24 0.35 0.72
Glu (μM) −0.035 0.028 −1.28 0.20
General memory
Gender (male) −0.071 0.63 −0.11 0.91
Education (years) 0.72 0.32 2.26 0.024
Glu (μM) −0.11 0.037 −3.01 2.8 × 10−3
Delayed recall
Gender (male) −0.24 0.59 −0.42 0.68
Education (years) 0.92 0.30 3.09 2.1 × 10−3
Glu (μM) −0.091 0.035 −2.6 9.6 × 10−3
Abbreviations: S.E. standard error.
106 Y. Kamada et al. / BBA Clinical 5 (2016) 101–107assessment of plasma transaminases, amino acids, and memory
functions were performed in the present study.
In conclusion, we demonstrate the signiﬁcant relationships among
plasma transaminases (AST and ALT), plasma glutamate levels, and
memory functions in 514 healthy subjects. Considering our ﬁndings,
we hypothesize that plasma transaminase elevation in obesity-
induced fatty liver patients evokes memory function disorders and
leads to food dependency, which results in further obesity (vicious
liver-brain cycle). Breaking up this vicious cycle should ameliorate met-
abolic syndrome progression.Transparency Document
The Transparency Document associated with this article can be
found, in the online version.Acknowledgments
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